Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to targeted therapy in chronic myelogenous leukemia.

Seminars in hematology - 1 Jan 2007

Hochhaus Andreas, Erben Philipp, Ernst Thomas, Mueller Martin C

Abstract excerpt

The advent of the Bcr-Abl selective tyrosine kinase inhibitor imatinib mesylate (Glivec, Gleevec, Novartis, East Hanover, NJ) has substantially changed the treatment landscape for chronic myelogenous leukemia (CML). However, some patients, primarily those with advanced disease, are either initially refractory to imatinib or eventually develop imatinib resistance. Imatinib resistance or intolerance frequently...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Pyrimidines

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 17292737
DOI: 10.1053/j.seminhematol.2006.12.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to targeted therapy in chronic myelogenous leukemia.PMID 17292737Read ↗

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.Semantic proximity Read ↗

Resistance to imatinib: mutations and beyond.Semantic proximity Read ↗

Clinical resistance to imatinib: mechanisms and implications.Semantic proximity Read ↗

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.Semantic proximity Read ↗

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistanceSemantic proximity Read ↗

Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.Semantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.Semantic proximity Read ↗

Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.Semantic proximity Read ↗

Treating imatinib-resistant leukemia: the next generation targeted therapies.Semantic proximity Read ↗

Resistance to Imatinib: Mechanisms and ManagementSemantic proximity Read ↗

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.